Should postmenopausal women over 60 years of age be prescribed hormone therapy?

Hormone Therapy for Women Over 60: Not Recommended for New Initiation

Women over 60 should generally NOT initiate hormone therapy, as the risks of cardiovascular disease, stroke, venous thromboembolism, dementia, and cancer significantly outweigh potential benefits at this age. 1

Guideline-Based Framework

The U.S. Preventive Services Task Force explicitly recommends against the use of menopausal hormone therapy in postmenopausal women for the prevention of chronic conditions 1. This recommendation is echoed by the American Heart Association, American Congress of Obstetricians and Gynecologists, Canadian Task Force on Preventive Health Care, and American Academy of Family Physicians 1.

The North American Menopause Society's 2022 position statement clarifies that for women initiating hormone therapy more than 10 years from menopause onset or aged older than 60 years, the benefit-risk ratio is unfavorable due to greater absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia 2.

Critical Evidence on Age-Related Risks

New Initiation After Age 65

The most recent 2026 study examining women initiating hormone therapy at age 65 or older found dramatically increased hazards:

• Any cancer: HR 2.22 (95% CI: 1.83-2.68)
• Cerebrovascular accident: HR 2.70 (95% CI: 2.36-3.08)
• Both hormone-sensitive AND non-hormone-sensitive cancers increased 3

This 2026 evidence strongly supports current guidelines discouraging late initiation 3.

Contradictory Evidence Requires Careful Interpretation

A 2024 Medicare study 4 showed apparent benefits of hormone therapy continuation beyond age 65, including mortality reduction (19%) and decreased risks of several conditions. However, this study examined women who CONTINUED therapy past 65, not those who newly initiated it—a critical distinction. Women who tolerated therapy well enough to continue likely represent a selected, healthier population with lower baseline risk.

Clinical Decision Algorithm

For Women Over 60 NOT Currently on Hormone Therapy:

1. Do NOT initiate systemic hormone therapy for chronic disease prevention 1
2. Do NOT initiate for cardiovascular protection at any age 1, 2
3. For bothersome genitourinary symptoms only: Consider low-dose vaginal estrogen (not systemic therapy) 2
4. For persistent severe vasomotor symptoms: Individualized risk assessment required, but generally avoid initiation after age 60 2

For Women Over 60 Currently on Hormone Therapy:

1. Reevaluate periodically for documented ongoing indications 2
2. If continuing for persistent vasomotor symptoms with shared decision-making, use lowest effective dose 2, 5
3. Consider discontinuation given increased risks, particularly if:
   • More than 5 years of combined estrogen-progestogen use (breast cancer risk) 6
   • No ongoing bothersome symptoms
   • Cardiovascular risk factors present

Key Risk Considerations by Age

The "timing hypothesis" or "window of opportunity" is crucial: Hormone therapy initiated within 10 years of menopause (typically age <60) may have cardiovascular benefits, while initiation after this window increases cardiovascular harm 2, 5, 6.

Specific Risks After Age 60:

• Cardiovascular: Increased coronary heart disease, stroke risk 1, 3, 2
• Thrombotic: Venous thromboembolism risk elevated 1, 2
• Cognitive: Increased dementia risk 1, 2
• Cancer: Elevated risk of multiple malignancies, both hormone-sensitive and non-hormone-sensitive 3

Common Pitfalls to Avoid

1. Do not confuse continuation with initiation: Evidence supporting continuation in select women does not justify new starts after 60 [4 vs 3]
2. Bioidentical hormones are not safer: FDA has not approved bioidentical hormone therapy for chronic disease prevention, and no randomized trials support their use 1
3. Do not prescribe for bone health alone: Other osteoporosis treatments have better risk profiles for women over 60 1
4. Avoid oral formulations if any therapy considered: Transdermal/vaginal routes have lower thrombotic risk than oral preparations 4, 5

Bottom Line for Clinical Practice

The evidence overwhelmingly supports NOT initiating hormone therapy in women over 60. The 2026 data showing increased cancer and cerebrovascular events with late initiation 3, combined with consistent guideline recommendations 1, 2, make this a clear clinical decision. For the rare woman over 60 with severe, persistent vasomotor symptoms unresponsive to non-hormonal treatments, any consideration of systemic hormone therapy requires explicit documentation of why risks are being accepted, use of the lowest possible dose, non-oral routes when feasible, and close monitoring with frequent reevaluation.